WO2011055796A1 - ピロロキノリンキノンのフリー体 - Google Patents
ピロロキノリンキノンのフリー体 Download PDFInfo
- Publication number
- WO2011055796A1 WO2011055796A1 PCT/JP2010/069734 JP2010069734W WO2011055796A1 WO 2011055796 A1 WO2011055796 A1 WO 2011055796A1 JP 2010069734 W JP2010069734 W JP 2010069734W WO 2011055796 A1 WO2011055796 A1 WO 2011055796A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- salt
- alkali metal
- metal salt
- pyrroloquinoline quinone
- Prior art date
Links
- MMXZSJMASHPLLR-UHFFFAOYSA-N OC(c1cc(C(C(c2nc(C(O)=O)cc(C(O)=O)c2-2)=O)=O)c-2[nH]1)=O Chemical compound OC(c1cc(C(C(c2nc(C(O)=O)cc(C(O)=O)c2-2)=O)=O)c-2[nH]1)=O MMXZSJMASHPLLR-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to a method for producing a free form of pyrroloquinoline quinone and a high-purity crystal obtained by the production method.
- PQQ Pyrroloquinoline quinone
- This PQQ is obtained by subjecting PQQ obtained by an organic chemical synthesis method (JACS, Vol. 103, pages 5599-5600 (1981)) or a fermentation method (Japanese Patent Laid-Open No. 1-218597) to chromatography,
- the PQQ section in the effluent can be concentrated, crystallized by crystallization (Japanese Patent No. 2072284), and dried.
- the crystals thus obtained are usually alkali metal salts, depending on the pH and precipitation conditions used.
- PQQ is required to be a free form for use as a raw material for derivative synthesis or as a product dissolved in an organic solvent that is insoluble in alkali metal salts.
- PQQ crystals are obtained by adjusting the pH to 2.5.
- PQQ is It was found to be a mono-alkali metal salt, not a free form.
- the structure of a free form has been reported (nature, vol. 280, 30 August, 1979, P844), which contains an acetone adduct.
- the present inventors have found that a free form of pyrroloquinoline quinone is precipitated when the pH of the solution in which the alkali metal salt of pyrroloquinoline quinone is dissolved is 1.5 or less (Examples 1 to 3). ). The present invention is based on this finding.
- the object of the present invention is to provide a method for producing a free form of pyrroloquinoline quinone easily and without using an organic solvent or an ion exchange resin, and a high-purity crystal thereof.
- a pyrroloquinoline quinone free form comprising: preparing a solution having a pH of 1.5 or less obtained by dissolving an alkali metal salt of the compound to obtain a precipitate;
- a production method (hereinafter sometimes referred to as “production method according to the present invention”) is provided.
- the formula (1) (Hereinafter, also referred to as “the compound according to the present invention”) is provided.
- a free form of pyrroloquinoline quinone having a high purity can be easily produced without using an organic solvent or an ion exchange resin and having a low alkali metal content and good crystallinity. It is.
- the PQQ-free body obtained in the present invention can be used as an active ingredient of a pharmaceutical or functional food, and is in the form of an external preparation for skin, injection, oral preparation, suppository, etc. It is advantageous in that it can be provided in the form of food, various hospital foods, and the like.
- FIG. 3 is a diagram showing the results of powder X-ray analysis of the PQQ-free body obtained in Example 1.
- a free form of pyrroloquinoline quinone can be produced by preparing a solution having a pH of 1.5 or less obtained by dissolving an alkali metal salt of pyrroloquinoline quinone and obtaining a precipitate.
- pyrroloquinoline quinone and “free form of pyrroloquinoline quinone” mean a compound represented by the following formula (1), and are used interchangeably to represent the compound.
- an alkali metal salt of pyrroloquinoline quinone means an alkali metal salt of a compound represented by the formula (1).
- pyrroloquinoline quinone free form crystal means a crystal of the compound represented by the formula (1), which is a state in which pyrroloquinoline quinone molecules are regularly aligned in a solid state. Specifically, it is a highly pure and highly stable state. Whether or not the compound of formula (1) (free form of pyrroloquinoline quinone) is in the form of crystals can be confirmed by detecting a peak by powder X-ray diffraction.
- the production method according to the present invention can be carried out by preparing a solution having a pH of 1.5 or less obtained by dissolving an alkali metal salt of pyrroloquinoline quinone and obtaining a precipitate.
- examples of the alkali metal salt of pyrroloquinoline quinone used as a raw material for producing a free form of pyrroloquinoline quinone include salts of sodium, potassium, lithium, cesium, rubidium and the like. These salts may be used alone or in combination. Preferably, it is a single salt of sodium or potassium, and a sodium salt is more preferable because it can be easily purchased.
- the substitution number of the salt in the alkali metal salt of pyrroloquinoline quinone is 1 to 3, and any of a monoalkali metal salt, a dialkali metal salt, and a trialkali metal salt is preferable, but a dialkali metal salt is preferable.
- the alkali metal salt of pyrroloquinoline quinone is particularly preferably a disodium salt.
- alkali metal salt a free body can be produced by precipitation in an aqueous solution having a pH of 1.5 or lower.
- alkaline earth metals, ammonium, organic ammonium salts, and transition metal salts can be similarly produced.
- alkali metal salt of pyrroloquinoline quinone used as a raw material in the present invention, commercially available products can be obtained.
- the alkali metal salt of pyrroloquinoline quinone used as a raw material in the present invention can be produced by a known method such as an organic chemical synthesis method or a fermentation method.
- the alkali metal salt of pyrroloquinoline quinone used as a raw material in the present invention may be crystalline or amorphous. Further, impurities may be included.
- an alkali metal salt of pyrroloquinoline quinone When used as a solution, it can be used by dissolving in a solvent such as water or alcohol, but it is preferably used as an aqueous solution of an alkali metal salt of pyrroloquinoline quinone.
- the solution of the alkali metal salt of pyrroloquinoline quinone can be prepared to be, for example, 0.001 to 1 w / w%, preferably 0.005 to 0.5 w / w%, more preferably 0.01 to 0.25 w / w%.
- the pH of the solution can be 3 or more and 13 or less, preferably 5 to 12, and more preferably 7 to 10.
- an alkaline substance for example, sodium hydroxide
- the temperature at this time can be 0 to 140 ° C., but preferably 20 to 90 ° C. does not require a special apparatus and is easy to use. In terms of solubility, a high temperature is easily dissolved, and therefore, it is preferably set to 50 ° C. or higher from the viewpoint of productivity.
- a solution having a pH of 1.5 or less prepared by dissolving an alkali metal salt of pyrroloquinoline quinone is prepared in order to precipitate the target free form of pyrroloquinoline quinone.
- Preparation of a solution having a pH of 1.5 or lower can be performed by using an acid.
- the pH of the solution can be 1.5 or less, preferably 1 or less. If the pH is 2 or more, the alkali metal remains, that is, a salt of 1 sodium salt or more. In order to prevent this, the pH used is preferably 1.5 or less, more preferably 1 or less. If the pH is not lowered at the time of precipitation, the precipitated crystal becomes a solid having a peak derived from the structure of one alkali metal salt.
- the pH of the solution can be 0.5 to 1.5, preferably 0.5 to 1, and more preferably 0.6 to 0.9.
- an acid is added to the alkali metal salt solution of pyrroloquinoline quinone to lower the pH. It can also be carried out by adding an alkali metal salt solution of pyrroloquinoline quinone to the acid solution.
- it can also be implemented by mixing the solid of the alkali metal salt of pyrroloquinoline quinone, and an acid. In this case, when an acid is added abruptly, the mixed state does not occur uniformly, so alkali metals are likely to remain, but the amount of water used is small and simple.
- a solution having a pH of 1.5 or less comprising an alkali metal salt of pyrroloquinoline quinone is represented by the following process (hereinafter also referred to as “preparation process”): (I) a step of adding an acid or an acidic solution to a solution obtained by dissolving an alkali metal salt of pyrroloquinoline quinone to bring the pH of the solution to 1.5 or less; (Ii) adding a solution obtained by dissolving an alkali metal salt of pyrroloquinoline quinone or an alkali metal salt of pyrroloquinoline quinone to an acidic solution to bring the pH of the solution to 1.5 or lower; or (iii) an acid It can be prepared by adding a solution prepared by dissolving an alkali metal salt of pyrroloquinoline quinone to bring the pH of the solution to 1.5 or less.
- it can be prepared by adding an acid or an acidic solution to a solution obtained by dissolving an alkali metal salt of pyrroloquinoline qui
- an additive can be added to an addition target at a time, or can be gradually added.
- the acid used in the preparation step is not particularly limited as long as the pH can be lowered.
- Either inorganic acid or organic acid can be used.
- examples of the inorganic acid include hydrochloric acid, hydrogen bromide, hydrogen iodide, perchloric acid, sulfuric acid, phosphoric acid, nitric acid, etc., preferably hydrochloric acid, hydrogen bromide, hydrogen iodide, perchlorine. Acid, phosphoric acid, nitric acid, more preferably hydrochloric acid.
- organic acid examples include acetic acid, formic acid, oxalic acid, lactic acid, and citric acid, and acetic acid, formic acid, oxalic acid, lactic acid, and citric acid are preferable. Since there is a risk of acid remaining in pyrroloquinoline quinone due to the low pH used, monovalent acids that have vapor pressure and are not toxic, such as hydrochloric acid, are most preferred. Further, hydrochloric acid gives a solid with high crystallinity which is also defined in the scope of the present invention, and is excellent in terms of crystallinity. Multivalent acids often have low solubility of salts with alkali metal ions and tend to remain in solids. Sulfuric acid is easy to use because it does not emit smoke, but it is preferable to combine with other acids because it tends to remain in a solid and there is a risk of discoloration due to its dehydrating property.
- the acid can be used alone or in combination of two or more, but at least hydrochloric acid is used, that is, hydrochloric acid alone or hydrochloric acid and one or more other acids (for example, hydrogen bromide, hydrogen iodide, Perchloric acid, sulfuric acid, phosphoric acid, nitric acid, etc.) are preferably used in combination.
- hydrochloric acid alone or hydrochloric acid and one or more other acids (for example, hydrogen bromide, hydrogen iodide, Perchloric acid, sulfuric acid, phosphoric acid, nitric acid, etc.) are preferably used in combination.
- Acid can be used as diluted acid (acidic solution).
- the acid can be used after being dissolved in a solvent such as water.
- the acidic solution can be prepared to be 0.1 to 20 g / L, for example, but preferably 0.5 to 10 g / L. *
- the molar ratio of the alkali metal salt of pyrroloquinoline quinone and the acid can be 1: 1 to 1: 1000, preferably 1: 2 to 1: 100.
- the temperature at which the preparation step is performed is not particularly limited, but can be set to ⁇ 20 ° C. to 140 ° C. from the standpoint of general handling. In order to increase the solubility of the alkali metal salt of pyrroloquinoline quinone, it can be heated.
- the time for carrying out the preparation process is not particularly limited, but it can be carried out in 5 minutes to 1 week. If the scale is small, it takes a short time, but if it is large, it takes a long time.
- a precipitate can be obtained from a solution having a pH of 1.5 or less obtained by dissolving an alkali metal salt of pyrroloquinoline quinone prepared by the above preparation step.
- precipitate means a solid phase (solid) appearing from a liquid phase (solution).
- a step of leaving a solution having a pH of 1.5 or less prepared by dissolving the alkali metal salt of pyrroloquinoline quinone prepared by the above preparation step (hereinafter referred to as “precipitation step”). May be implemented).
- the solution may be stirred.
- the temperature at which the precipitation step is performed is not particularly limited, but can be set to ⁇ 20 ° C. to 100 ° C. from the viewpoint of general handling. At the time of precipitation, the lower temperature is more likely to be precipitated, so that the temperature can be preferably ⁇ 10 to 70 ° C., more preferably 0 to 50 ° C.
- the time for performing the precipitation step is not particularly limited, but is 1 minute to 1 week, preferably 30 minutes to 1 hour.
- the precipitated solid can be separated from the liquid using a known method such as filtration or centrifugation. This may be washed with water or a hydrochloric acid solution, and further washed with an organic solvent such as isopropanol if necessary.
- the obtained solid can be dehydrated by air drying and drying under reduced pressure.
- the production method according to the present invention can be carried out as follows: An alkali metal salt of pyrroloquinoline quinone is dissolved in water.
- the pH at this time is desirably 3 or more and 13 or less, and more preferably 5 to 12.
- an alkaline solution may be added to adjust the pH.
- the temperature at this time may be 0 to 140 ° C., but it is preferably 20 to 90 ° C., and no special equipment is required, and it is easy to use. In terms of solubility, high temperatures are easy to dissolve, so setting it to 50 ° C. or higher increases productivity.
- a solid is precipitated by adding an acid to this solution and lowering it to the range of the present invention.
- the solid that has been prepared and precipitated under these conditions is a free form of pyrroloquinoline quinone, and 12.4 °, 15.5 °, and 16.6 as 2 ⁇ peaks using Cu K ⁇ radiation in powder X-ray diffraction. It is a crystal of pyrroloquinoline quinone showing °, 18.2 °, 24.0 °, 24.9 °, 28.0 ° (all within the range of ⁇ 0.2 °).
- these peaks can also be observed with a general powder X-ray diffractometer equipped with a monochromator. Since the crystal form defined in the present invention includes a measurement error, it is only necessary to have a reasonable identity regarding the angle of the peak.
- a method for producing a compound represented by formula (1) (free form of pyrroloquinoline quinone), wherein an alkali metal salt of a compound represented by formula (1) is dissolved.
- An acid or acidic solution is added to the resulting aqueous solution to prepare a solution having a pH of 1.5 or lower, and a precipitate is obtained.
- the alkali metal salt is a sodium salt, potassium salt, lithium salt, cesium salt.
- the acid is preferably selected from the group consisting of hydrochloric acid, hydrogen bromide, hydrogen iodide, perchloric acid, phosphoric acid, nitric acid, acetic acid, formic acid, oxalic acid, lactic acid and citric acid.
- a production method is provided that is a combination of one or two or more selected acids, and preferably has a pH of 1 or less.
- a process for producing a compound represented by formula (1) (free form of pyrroloquinoline quinone), wherein an alkaline solution of the compound represented by formula (1) is added to an acidic solution. Adding a metal salt or an aqueous solution in which the alkali metal salt is dissolved to prepare a solution having a pH of 1.5 or lower, and obtaining a precipitate.
- the alkali metal salt is a sodium salt or a potassium salt.
- the acid is hydrochloric acid, hydrogen bromide, hydrogen iodide, perchloric acid, phosphoric acid, nitric acid, acetic acid, formic acid, oxalic acid, lactic acid and
- a production method is provided which is a combination of one or two or more acids selected from the group consisting of citric acid, and preferably has a pH of 1 or less.
- a process for producing a compound represented by formula (1) (free form of pyrroloquinoline quinone), wherein an alkali metal salt of the compound represented by formula (1) is dissolved.
- An acid or acidic solution is added to the resulting aqueous solution to prepare a solution having a pH of 1.5 or less, and a precipitate is obtained.
- the alkali metal salt is a sodium salt, potassium salt, lithium salt, cesium Selected from the group consisting of a salt and a rubidium salt.
- the acid is one or a combination of two or more acids including at least hydrochloric acid, and preferably has a pH of 1 or less. .
- the free form obtained by the present invention has a low alkali metal content and high crystallinity, so that the purity is high.
- This diffraction peak can be distinguished from disodium salt and monosodium salt, and is effective for quality control.
- the free form of pyrroloquinoline quinone obtained by the production method according to the present invention can be used as an active ingredient of a pharmaceutical or functional food, and is in the form of an external preparation for skin, injection, oral preparation, suppository, etc. Can be provided in the form of food and drink, nutrition-enhanced food, various hospital foods, etc.
- saccharides such as water, fructose and glucose, oils such as falling raw oil, soybean oil and olive oil, and glycols such as polyethylene glycol and polypropylene glycol are used as the liquid agent. it can.
- solid preparations such as tablets, capsules, granules, etc.
- sugars such as lactose, sucrose, mannitol, etc., kaolin, talc, magnesium stearate etc. as lubricants, starch, sodium alginate as disintegrants
- binder examples include polyvinyl alcohol, cellulose, and gelatin
- surfactant include fatty acid esters
- plasticizer include glycerin and the like, but are not limited thereto. You may add a dissolution accelerator, a filler, etc. as needed.
- pyrroloquinoline quinone can be used alone or in combination with other materials.
- Materials that can be combined include vitamins such as vitamin B group, vitamin C ⁇ ⁇ ⁇ ⁇ and vitamin E, amino acids, carotenoids such as astaxanthin, ⁇ -carotene and ⁇ -carotene, ⁇ 3 fatty acids such as docosahexaenoic acid and eicosapentaenoic acid Examples thereof include ⁇ 6 fatty acids such as arachidonic acid, but are not limited thereto.
- the present invention further provides the following inventions.
- the acid used for precipitating pyrroloquinoline quinone is selected from hydrochloric acid, hydrogen bromide, hydrogen iodide, perchloric acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, formic acid, oxalic acid, lactic acid and citric acid.
- Example 1 As a raw material PQQ disodium salt, a reagent (trade name: Bio PQQ) manufactured by Mitsubishi Gas Chemical Co., Ltd. was used. The purity of the PQQ disodium salt by high-performance liquid chromatography UV absorption was 99.0%.
- Example 2 The raw material of Example 1 (PQQ disodium salt) was dissolved in water, the pH was adjusted to pH 8 with sodium hydroxide, sodium chloride was added to precipitate PQQ trisodium salt, washed with ethanol and dried. This was used for the experiment.
- PQQ trisodium salt 0.9 g was dissolved in water (60 g). About 2 g of concentrated hydrochloric acid was added to this while stirring. The pH of the obtained solution was 0.6. After stirring overnight, the mixture was filtered, washed with isopropanol, and dried under reduced pressure to obtain 0.35 g of a red solid. The results of powder X-ray diffraction and Na analysis of the obtained red solid were the same as those in Example 1, with no residual sodium and free crystals.
- Example 3 The same PQQ disodium salt 1 g as in Example 1 was added to a mixture of 3.5 g of concentrated hydrochloric acid and 3.5 g of water, and the pH of the resulting solution was adjusted to 1. Stirring was carried out at room temperature for 1 hour, filtered and washed with water. Drying under reduced pressure gave 0.79 g of a red solid. The resulting red solid had a sodium / PQQ molar ratio of 0.06, with some sodium remaining.
- Comparative Example 1 The same raw material (PQQ disodium salt) as in Example 1 was used and the operation was carried out in the same manner. However, hydrochloric acid was added to adjust the pH of the solution to 2.3, and 1.75 g of a red solid was precipitated.
- the molar ratio of sodium / PQQ was 0.96 and it was a monosodium salt.
- the powder X-ray diffraction data at this time shows 8.5, 11.9, 15.7, 16.9, 24.4, 27.3 as 2 ⁇ peaks using Cu K ⁇ radiation in powder X-ray diffraction. It was. The peak was different from the free body.
- Comparative Example 2 The same operation as in Comparative Example 1 was performed. However, 4N sulfuric acid was used to adjust the pH, the pH of the solution was adjusted to 2.5, and 1.71 g of a red solid was obtained.
- Comparative Example 3 The experiment was conducted using the same raw material (PQQ disodium salt) as in Example 1 as a solid. 2 g of PQQ disodium salt was added to 200 g of 4N sulfuric acid to adjust the pH to 0.6 to obtain 1.66 g of a brown solid.
- the molar ratio of sodium / PQQ was 0.96, which was in the range of monosodium salt.
- the powder X-ray diffraction data showed a spectrum without a clear peak and low crystallinity. It was a broad peak centered at 26.6 as a 2 ⁇ peak using Cu K ⁇ radiation by powder X-ray diffraction. In this case, sodium remained, discoloration occurred, and the crystallinity was low.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
(i)ピロロキノリンキノンのアルカリ金属塩を溶解してなる溶液に、酸または酸性溶液を添加し、該溶液のpHを1.5以下にする工程;
(ii)酸性溶液に、ピロロキノリンキノンのアルカリ金属塩またはピロロキノリンキノンのアルカリ金属塩を溶解してなる溶液を添加し、該溶液のpHを1.5以下にする工程;または
(iii)酸に、ピロロキノリンキノンのアルカリ金属塩を溶解してなる溶液を添加し、該溶液のpHを1.5以下にする工程
を実施することにより調製することができる。好ましくは、ピロロキノリンキノンのアルカリ金属塩を溶解してなる溶液に、酸または酸性溶液を添加し、該溶液のpHを1.5以下に調整する工程を実施することにより調製することができる。
ピロロキノリンキノンのアルカリ金属塩を水に溶解させる。このときのpHは3以上で13以下であることが望ましく、より好ましくは5から12である。この時にpH調整のためにアルカリ性の溶液を加えて調整してもよい。このときの温度は0から140℃で使用すれは良いが、好ましくは20から90℃が特別な装置も要らず、使用しやすい。溶解度の面では高い温度が溶解しやすいため、50℃以上にするのが生産性を高める。この溶液に酸を加え、本発明の範囲まで下げることで固体が析出する。または、アルカリ金属塩の溶液を酸性溶液の中に添加することで析出させることができる。固体のアルカリ金属塩を粉末として酸性溶液に添加することでも製造できる。pHを返すために混合する時は攪拌しながらするとアルカリ金属の残留を抑制することができる。
<粉末X線回折による回折角2θの測定条件>
装置:株式会社マックサイエンス製M18XCE
X線:Cu/管電圧40kV/管電流100mA
発散スリット:1°
散乱スリット:1°
受光スリット:0.3mmスキャンスピード:4.000°/min
サンプリング幅:0.020°
(1)ピロロキノリンキノンのアルカリ金属塩をpH1.5以下の水溶液中で析出させることを特徴とするフリー体の製造方法。
(2)ピロロキノリンキノンのアルカリ金属塩がナトリウム塩、カリウム塩、リチウム塩、セシウム塩及びルビジュウム塩から選択されることを特徴とする(1)記載のフリー体の製造方法。
(3)ピロロキノリンキノンのアルカリ金属塩がジナトリウム塩であることを特徴とする(1)記載のフリー体の製造方法。
(4)ピロロキノリンキノンを析出する際に使用する酸が塩酸、臭化水素、ヨウ化水素、過塩素酸、硫酸、燐酸、硝酸、酢酸、蟻酸、シュウ酸、乳酸及びクエン酸から選択されることを特徴とする(1)~(3)のいずれかに記載のフリー体の製造方法。
(5)粉末X線回折でCu Kα放射線を用いた2θのピークとして12.4°、15.5°、16.6°、18.2°、24.0°、24.9°、28.0°を示すピロロキノリンキノンの結晶。
[PQQ分析]
装置: 島津製作所、高速液体クロマトグラフィー、LC-20A
カラム:YMC-Pack ODS-TMS(5μm)、150x4.6mm I.D.
測定温度:40℃
検出:260nmにおける吸光度
溶離液:100mM CH3COOH/100mM CH3COONH4 (30/70, pH5.1)
溶出速度:1.5mL/min
[Na分析]
ポンプ: 島津製作所、LC-6A
カラムオーブン:島津製作所、HIC-6A
測定温度:40℃
検出器:東ソー株式会社、電気伝導度計CM-8000
カラム:昭和電工株式会社、Shodex、IC Y-521
溶離液:4mM HNO3
溶出速度:1.0mL/min
[粉末X線回折]
装置:株式会社マックサイエンス製M18XCE
X線:Cu/管電圧40kV/管電流100mA
発散スリット:1°
散乱スリット:1°
受光スリット:0.3mmスキャンスピード:4.000°/min
サンプリング幅:0.02
原料のPQQジナトリウム塩は三菱ガス化学社製の試薬(商品名:バイオPQQ)を使用した。PQQジナトリウム塩の、高速液体クロマトグラフィーのUV吸収による純度は99.0%であった。
実施例1の原料(PQQジナトリウム塩)を水に溶かし、pHを水酸化ナトリウムでpH8にして、食塩を加えてPQQトリナトリウム塩を析出させ、エタノールで洗浄し乾燥した。これを実験に使用した。
実施例1と同じPQQジナトリウム塩1gの固体を、濃塩酸3.5gと水3.5gの混合液に加え、得られた溶液のpHを1とした。攪拌を室温で1時間行い、ろ過し、水で洗った。減圧乾燥して、赤色固体0.79gを得た。得られた赤色固体におけるナトリウム/PQQのモル比は0.06で、わずかにナトリウムが残留した。
実施例1と同じ原料(PQQジナトリウム塩)を使用し、操作を同じように行った。ただし、塩酸を加えて、溶液のpHを2.3とし、赤色固体1.75gを析出させた。
比較例1と同様の操作を行った。ただし、pHをあわせるのに4N 硫酸を使用し、溶液のpHを2.5にし、赤色の固体1.71gを得た。
実施例1と同様の原料(PQQジナトリウム塩)を固体として使用して実験を行った。4N 硫酸200gにPQQジナトリウム塩2gを添加し、pH0.6にし、茶色固体1.66gを得た。
Claims (10)
- アルカリ金属塩が、ナトリウム塩、カリウム塩、リチウム塩、セシウム塩およびルビジュウム塩から選択される、請求項1に記載の製造方法。
- アルカリ金属塩が、ジアルカリ金属塩である、請求項1に記載の製造方法。
- アルカリ金属塩が、ジナトリウム塩である、請求項1に記載の製造方法。
- pH1.5以下の溶液が、酸を使用することにより調製される、請求項1に記載の製造方法。
- 酸が、塩酸、臭化水素、ヨウ化水素、過塩素酸、硫酸、燐酸、硝酸、酢酸、蟻酸、シュウ酸、乳酸およびクエン酸から選択される1種または2種以上の組み合わせである、請求項5に記載の製造方法。
- 式(1)で表される化合物が、結晶の形態である、請求項1~6のいずれかに記載の製造方法。
- 粉末X線回折でCu Kα放射線を用いた2θのピークとして12.4°、15.5°、16.6°、18.2°、24.0°、24.9°、28.0°(いずれも±0.2°)を示す、請求項9に記載の結晶。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/508,106 US20120226045A1 (en) | 2009-11-06 | 2010-11-05 | Pyrroloquinoline quinone in free form |
JP2011539405A JPWO2011055796A1 (ja) | 2009-11-06 | 2010-11-05 | ピロロキノリンキノンのフリー体 |
EP10828355.7A EP2497769A4 (en) | 2009-11-06 | 2010-11-05 | PYRROLOCHINOLINCHINONE IN FREE FORM |
CN2010800503602A CN102596952A (zh) | 2009-11-06 | 2010-11-05 | 游离形式的吡咯并喹啉醌 |
CA2779539A CA2779539A1 (en) | 2009-11-06 | 2010-11-05 | Pyrroloquinoline quinone in free form |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009255056 | 2009-11-06 | ||
JP2009-255056 | 2009-11-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011055796A1 true WO2011055796A1 (ja) | 2011-05-12 |
Family
ID=43970032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2010/069734 WO2011055796A1 (ja) | 2009-11-06 | 2010-11-05 | ピロロキノリンキノンのフリー体 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20120226045A1 (ja) |
EP (1) | EP2497769A4 (ja) |
JP (1) | JPWO2011055796A1 (ja) |
CN (1) | CN102596952A (ja) |
CA (1) | CA2779539A1 (ja) |
WO (1) | WO2011055796A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012173217A1 (ja) * | 2011-06-16 | 2012-12-20 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンジナトリウム塩の結晶およびその製造方法 |
CN103536593A (zh) * | 2012-07-12 | 2014-01-29 | 常茂生物化学工程股份有限公司 | 吡咯并喹啉醌在制备防治肿瘤药物的用途 |
WO2014027669A1 (ja) * | 2012-08-17 | 2014-02-20 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物 |
JP2017031126A (ja) * | 2015-08-06 | 2017-02-09 | 三菱瓦斯化学株式会社 | ピロロキノリンキノン結晶の製造方法 |
WO2018003531A1 (ja) * | 2016-06-29 | 2018-01-04 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンモノナトリウム及びその製造方法、並びにそれを含む組成物 |
JP2018533623A (ja) * | 2015-11-02 | 2018-11-15 | ジュチェン ハウテン ファーム カンパニー リミテッドZhucheng Haotian Pharm Co.,Ltd | ピロロキノリンキノンのb結晶形およびその製造方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA39715A (fr) * | 2014-04-16 | 2015-10-22 | Anthem Biosciences Private Ltd | Formes polymorphes de l'acide 4,5-dihydro-1h-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylique et de son sel de disodium, procédé de préparation desdites formes polymorphes et leur utilisation |
CN105315278B (zh) * | 2015-11-02 | 2018-01-16 | 诸城市浩天药业有限公司 | 吡咯喹啉醌a晶型及其制备方法 |
CN107163040B (zh) * | 2017-05-22 | 2019-08-06 | 山东金城生物药业有限公司 | 吡咯喹啉醌单钠盐晶体及其制备方法 |
CN112125899B (zh) * | 2019-06-24 | 2023-01-03 | 浙江可明生物医药有限公司 | 吡咯并喹啉醌二钠盐结晶、其制备方法及包含其的组合物 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01156903A (ja) * | 1987-09-03 | 1989-06-20 | Mitsubishi Gas Chem Co Inc | 花粉発芽促進剤 |
JPH01218597A (ja) | 1988-02-26 | 1989-08-31 | Mitsubishi Gas Chem Co Inc | ピロロキノリンキノンの製造方法 |
JPH0272284A (ja) | 1988-09-07 | 1990-03-12 | Yuukoushiya:Kk | 電磁作動水栓 |
WO2006102642A1 (en) * | 2005-03-24 | 2006-09-28 | Clf Medical Technology Acceleration Program, Inc. | Synthesis of pyrroloquinoline quinone (pqq) |
WO2008029907A1 (fr) * | 2006-09-08 | 2008-03-13 | Kyowa Hakko Bio Co., Ltd. | Agent améliorant l'hypertension |
WO2008035686A1 (fr) * | 2006-09-19 | 2008-03-27 | Kyowa Hakko Bio Co., Ltd. | Agent pour améliorer la résistance à l'insuline |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101193888A (zh) * | 2005-03-24 | 2008-06-04 | Clf医疗技术加速程序有限公司 | 吡咯喹啉醌(pqq)的合成方法 |
-
2010
- 2010-11-05 JP JP2011539405A patent/JPWO2011055796A1/ja active Pending
- 2010-11-05 WO PCT/JP2010/069734 patent/WO2011055796A1/ja active Application Filing
- 2010-11-05 CA CA2779539A patent/CA2779539A1/en not_active Abandoned
- 2010-11-05 US US13/508,106 patent/US20120226045A1/en not_active Abandoned
- 2010-11-05 CN CN2010800503602A patent/CN102596952A/zh active Pending
- 2010-11-05 EP EP10828355.7A patent/EP2497769A4/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01156903A (ja) * | 1987-09-03 | 1989-06-20 | Mitsubishi Gas Chem Co Inc | 花粉発芽促進剤 |
JPH01218597A (ja) | 1988-02-26 | 1989-08-31 | Mitsubishi Gas Chem Co Inc | ピロロキノリンキノンの製造方法 |
JPH0272284A (ja) | 1988-09-07 | 1990-03-12 | Yuukoushiya:Kk | 電磁作動水栓 |
WO2006102642A1 (en) * | 2005-03-24 | 2006-09-28 | Clf Medical Technology Acceleration Program, Inc. | Synthesis of pyrroloquinoline quinone (pqq) |
WO2008029907A1 (fr) * | 2006-09-08 | 2008-03-13 | Kyowa Hakko Bio Co., Ltd. | Agent améliorant l'hypertension |
WO2008035686A1 (fr) * | 2006-09-19 | 2008-03-27 | Kyowa Hakko Bio Co., Ltd. | Agent pour améliorer la résistance à l'insuline |
Non-Patent Citations (5)
Title |
---|
JACS, vol. 103, 1981, pages 5599 - 5600 |
NATURE, vol. 280, 30 August 1979 (1979-08-30), pages 844 |
NATURE, vol. 422, 24 April 2003 (2003-04-24) |
See also references of EP2497769A4 * |
VAN DER MEER, R.A. ET AL.: "Isolation, preparation, and assay of pyrroloquinoline quinone", METHODS IN ENZYMOLOGY, vol. 188, 1990, pages 260 - 283, XP008155490 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012173217A1 (ja) * | 2011-06-16 | 2012-12-20 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンジナトリウム塩の結晶およびその製造方法 |
JPWO2012173217A1 (ja) * | 2011-06-16 | 2015-02-23 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンジナトリウム塩の結晶およびその製造方法 |
US9174983B2 (en) | 2011-06-16 | 2015-11-03 | Mitsubishi Gas Chemical Company, Inc. | Pyrroloquinoline quinone disodium salt crystal and method for producing the same |
CN103536593A (zh) * | 2012-07-12 | 2014-01-29 | 常茂生物化学工程股份有限公司 | 吡咯并喹啉醌在制备防治肿瘤药物的用途 |
WO2014027669A1 (ja) * | 2012-08-17 | 2014-02-20 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物 |
US9394298B2 (en) | 2012-08-17 | 2016-07-19 | Mitsubishi Gas Chemical Company, Inc. | Pyrroloquinoline quinone tetraalkali salt and crystal thereof, methods for producing these, and composition |
JPWO2014027669A1 (ja) * | 2012-08-17 | 2016-07-28 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物 |
JP2017031126A (ja) * | 2015-08-06 | 2017-02-09 | 三菱瓦斯化学株式会社 | ピロロキノリンキノン結晶の製造方法 |
US10562895B2 (en) | 2015-11-02 | 2020-02-18 | Zhucheng Haotian Pharm Co., Ltd. | Pyrroloquinoline quinone B crystal form and preparation method therefor |
JP2018533623A (ja) * | 2015-11-02 | 2018-11-15 | ジュチェン ハウテン ファーム カンパニー リミテッドZhucheng Haotian Pharm Co.,Ltd | ピロロキノリンキノンのb結晶形およびその製造方法 |
KR20190022560A (ko) * | 2016-06-29 | 2019-03-06 | 미쯔비시 가스 케미칼 컴파니, 인코포레이티드 | 피로로퀴놀린퀴논모노나트륨 및 그 제조방법, 그리고 이것을 포함하는 조성물 |
JPWO2018003531A1 (ja) * | 2016-06-29 | 2019-04-18 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンモノナトリウム及びその製造方法、並びにそれを含む組成物 |
WO2018003531A1 (ja) * | 2016-06-29 | 2018-01-04 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンモノナトリウム及びその製造方法、並びにそれを含む組成物 |
US11021476B2 (en) | 2016-06-29 | 2021-06-01 | Mitsubishi Gas Chemical Company, Inc. | Pyrroloquinoline quinone monosodium and method for producing the same, and composition comprising the same |
KR102479748B1 (ko) | 2016-06-29 | 2022-12-21 | 미쯔비시 가스 케미칼 컴파니, 인코포레이티드 | 피로로퀴놀린퀴논모노나트륨 및 그 제조방법, 그리고 이것을 포함하는 조성물 |
JP7335070B2 (ja) | 2016-06-29 | 2023-08-29 | 三菱瓦斯化学株式会社 | ピロロキノリンキノンモノナトリウム及びその製造方法、並びにそれを含む組成物 |
Also Published As
Publication number | Publication date |
---|---|
EP2497769A1 (en) | 2012-09-12 |
CA2779539A1 (en) | 2011-05-12 |
JPWO2011055796A1 (ja) | 2013-03-28 |
US20120226045A1 (en) | 2012-09-06 |
CN102596952A (zh) | 2012-07-18 |
EP2497769A4 (en) | 2013-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011055796A1 (ja) | ピロロキノリンキノンのフリー体 | |
JP5842819B2 (ja) | ピロロキノリンキノンのカルシウム塩 | |
EP2455379B1 (en) | Crystals of pyrroloquinolinequinone sodium salts | |
US8946423B2 (en) | Highly soluble salt of pyrroloquinoline quinone and method for producing the same | |
JP6160621B2 (ja) | ピロロキノリンキノンテトラアルカリ塩及びその結晶、これらの製造方法、並びに、組成物 | |
CN101143863A (zh) | 5-甲基四氢叶酸的拆分及其成盐方法 | |
JP2016504277A (ja) | ピロロキノリンキノン二ナトリウム塩の結晶 | |
EP2537848A1 (en) | Method for producing reduced pyrroloquinoline quinone | |
JP5636671B2 (ja) | ピロロキノリンキノンLi塩の製造方法 | |
JP6217323B2 (ja) | ピロロキノリンキノンの製造方法 | |
KR20190022560A (ko) | 피로로퀴놀린퀴논모노나트륨 및 그 제조방법, 그리고 이것을 포함하는 조성물 | |
JP6428527B2 (ja) | ピロロキノリンキノン結晶の製造方法 | |
JP6395101B2 (ja) | イミダゾピロロキノリン塩 | |
WO2022076623A1 (en) | Process for racemizing and isolating atropisomers of 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione | |
US10131661B2 (en) | High-solubility acetone-added pyrroloquinoline quinone salt | |
CN104610180A (zh) | 一种奥替拉西钾的制备方法 | |
CN102372719B (zh) | 培美曲塞二甲酯对甲苯磺酸盐晶型及其制备方法 | |
JP2012136465A (ja) | ピロロキノリンキノンカリウム塩 | |
CN104725471B (zh) | 一种制备他替瑞林β晶型的方法 | |
JP2013082706A (ja) | 5−ヒドロキシ−1h−イミダゾール−4−カルボキサミド水和物の結晶 | |
CN104447513A (zh) | 一种高纯度盐酸马尼地平β晶型的制备方法 | |
JP2015051933A (ja) | クロロゲン酸の製造方法及びクロロゲン酸金属錯体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080050360.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10828355 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011539405 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010828355 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2779539 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13508106 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |